Tricyclo Ring System Having The Hetero Ring As One Of The Cyclos Patents (Class 549/458)
-
Patent number: 11560363Abstract: Provided are novel prodrugs of esuberaprost and pharmaceutical compositions thereof, as well as methods of making and methods of using these prodrugs.Type: GrantFiled: October 17, 2019Date of Patent: January 24, 2023Assignee: United Therapeutics CorporationInventors: Hitesh Batra, Liang Guo
-
Patent number: 11414394Abstract: A process for producing a hydrate of a hydrochloride salt of 2,2?-((((((2-acetylnaphtho[2,3-b]furan-4,9-diyl)bis(oxy))bis(carbonyl))bis(azanediyl))bis(ethane-2,1-diyl))bis(azanediyl))diacetic acid of the formula: wherein the process comprises the following step: recrystallizing the hydrochloride salt of 2,2?-((((((2-acetylnaphtho[2,3-b]furan-4,9-diyl)bis(oxy))bis(carbonyl))bis(azanediyl))bis(ethane-2,1-diyl))bis(azanediyl))diacetic acid, in the presence of hydrochloric acid and a recrystallization solvent; wherein the recrystallization solvent is methanol, ethanol, 2-propanol, diethyl ether, ethyl acetate, benzene, toluene, acetone, dichloromethane, chloroform, hexane, dimethylformamide, acetonitrile, or water; or mixed solvent thereof.Type: GrantFiled: August 28, 2020Date of Patent: August 16, 2022Assignees: SUMITOMO PHARMA ONCOLOGY, INC., SUMITOMO PHARMA CO., LTD.Inventors: Hitoshi Ban, Seiji Kamioka, Yusuke Sawayama, Chiang Jia Li
-
Patent number: 11401541Abstract: A solid form of (?)-Ambrox formed by a bioconversion process.Type: GrantFiled: October 14, 2020Date of Patent: August 2, 2022Assignee: Givaudan S.A.Inventors: Ghislain Sanhaji, Alix Rousseaux, Sandrine Noel, Eric Eichhorn
-
Patent number: 11358944Abstract: The present invention provides compounds as represented by structural formula (I). In formula (I), R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, and R14 are separately H or deuterium (D) independently. Moreover, at least one of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, and R14 must be D. Also provided is use of any of the compounds or its pharmaceutical composition in the preparation of a drug for treating an anxiety.Type: GrantFiled: November 18, 2019Date of Patent: June 14, 2022Assignee: BEIJING JUNKE HUAYUAN MED TECH CO., LTD.Inventors: Bohua Zhong, Jiajun Yang
-
Patent number: 11028096Abstract: Various embodiments relate to a compound of the formula (I) and (II), wherein X, X1, X2, X3, and R1-R4 are defined herein, as well as pharmaceutical compositions comprising compounds of the formula (I) and/or (II) and methods of treating an HIV infection comprising administering a therapeutically effective amount of one or more compounds of formula (I) and/or (II), or a pharmaceutical composition comprising compounds of the formula (I) and/or (II), to a patient in need thereof.Type: GrantFiled: November 9, 2017Date of Patent: June 8, 2021Assignee: Purdue Research FoundationInventors: Arun K. Ghosh, Hiroaki Mitsuya, Prasanth Reddy Nyalapatla
-
Patent number: 10844412Abstract: A solid form of (?)-Ambrox formed by a bioconversion process.Type: GrantFiled: April 20, 2017Date of Patent: November 24, 2020Assignee: Givaudan S. A.Inventors: Ghislain Sanhaji, Alix Rousseaux, Sandrine Noel, Eric Eichhorn
-
Patent number: 10800752Abstract: The present invention provides compounds represented by formula (1A), or pharmaceutically acceptable salts. Compounds represented by formula (1A), or pharmaceutically acceptable salts thereof, wherein A1 and A2 are identical or different, and each independently —C(?O)B, —C(?O)CR3AR3BB, —CO2B, —C(?S)OB, —CONR3CB, —C(?S)NR3CB, a hydrogen atom, or the like, wherein A1 and A2 are not both hydrogen atoms, wherein B is an optionally substituted 3- to 12-membered monocyclic or polycyclic heterocyclic group, an optionally substituted 3- to 12-membered cyclic amino group, or a group represented by the following formula (B), wherein the 3- to 12-membered monocyclic or polycyclic heterocyclic group and the 3- to 12-membered cyclic amino group have at least one or more secondary nitrogen atoms in the ring; R1 is a hydrogen atom or the like; R2A, R2B, R2C, and R2D are identical or different, and each independently a hydrogen atom or the like; and R8 is alkyl. wherein * denotes a bonding position.Type: GrantFiled: November 19, 2018Date of Patent: October 13, 2020Assignees: BOSTON BIOMEDICAL, INC., SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Hitoshi Ban, Seiji Kamioka, Yusuke Sawayama, Chiang Jia Li
-
Patent number: 10738023Abstract: Provided is a method for producing a 2-alkylcarbonylnaphtho[2,3-b]furan-4,9-dione-related substance, which is suitable for the production on an industrial scale. The present invention provides: a method for producing an intermediate for the production of a 2-alkylcarbonyl[2,3-b]furan-4,9-dione, which comprises reacting a 1-butyne derivative in which a ketone or an alcohol is protected with a 2-hydroxy-1,4-naphthoquinone derivative having a leaving group at position-3 in a solvent in the presence of a metal or a metal compound and a base; and a substance relating to the intermediate.Type: GrantFiled: March 24, 2017Date of Patent: August 11, 2020Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.Inventors: Kazuhiko Takahashi, Shoji Watanabe, Katsuya Uchiyama, Kento Senami
-
Patent number: 10710973Abstract: An improved method is described for making single isomers of synthetic benzoprostacyclin analogue compounds, in particular the pharmacologically active 314-d isomer of beraprost. In contrast to the prior art, the method is stereoselective and requires fewer steps than the known methods for making these compounds.Type: GrantFiled: March 1, 2019Date of Patent: July 14, 2020Assignee: Lung Biotechnology PBCInventors: Vijay Sharma, Hitesh Batra, Sudersan Tuladhar
-
Patent number: 10633314Abstract: A method of selective conversion of Abienol, represented by formula 1, to Sclareodiol, represented by formula 2 by ozonolysis and subsequent reduction. The ozonolysis is carried out at temperatures above ?60° C., preferably in nonhalogenated solvents. R is selected from H, acetals, aminals, optionally substituted alkyl groups, such as benzyl group, carboxylates such as acetates or formates, carbonates such as methyl or ethyl carbonates, carbamates, and any protecting group which can be attached to 1 and cleaved from 2, R? is selected from CH?CH2, an alkyl moiety with C2-C20, e.g. CH2—CH3, or a cycloalkyl or polycycloalkyl moiety with C3-C20, e.g. cyclopropyl, optionally alkylated, respectively, and the wavy bond is depicting an unspecified configuration of the adjacent double bond between C2 and C3.Type: GrantFiled: March 17, 2016Date of Patent: April 28, 2020Assignee: GIVAUDAN S.A.Inventor: Fridtjof Schröder
-
Patent number: 10577341Abstract: The present invention provides a monohydrated form of Beraprost-314d, and a novel crystalline form of Beraprost-314d monohydrate, and processes for the preparation thereof.Type: GrantFiled: November 26, 2018Date of Patent: March 3, 2020Assignee: CHIROGATE INTERNATIONAL INC.Inventors: Shih-Yi Wei, Jian-Bang Jheng
-
Patent number: 10329332Abstract: A film of the present invention contains a polypeptide derived from spider silk proteins. The decomposition temperature of the film is 240 to 260° C. The film absorbs ultraviolet light having a wavelength of 200 to 300 nm and has a light transmittance of 85% or more at a wavelength of 400 to 780 nm. The film is transparent and colorless in a visible light region. A method for producing a film of the present invention includes: dissolving a polypeptide derived from spider silk proteins in a dimethyl sulfoxide solvent to prepare a dope; and cast-molding the dope on a surface of a base. Thus, the present invention provides a spider silk protein film that can be formed easily and has favorable stretchability, and a method for producing the same.Type: GrantFiled: December 17, 2013Date of Patent: June 25, 2019Assignee: SPIBER INC.Inventors: Kaori Sekiyama, Mizuki Ishikawa, Shinya Murata
-
Patent number: 10294211Abstract: A method of isolating and purifying (?)-Ambrox from a reaction mixture comprising (?)-Ambrox and one or more of the compounds (II), (III) and (IV)Type: GrantFiled: April 22, 2016Date of Patent: May 21, 2019Assignee: Givaudan S.A.Inventor: Eric Eichhorn
-
Patent number: 10246430Abstract: The present invention is directed to methods for preparing Beraprost and novel synthetic intermediates for Beraprost.Type: GrantFiled: May 4, 2018Date of Patent: April 2, 2019Assignee: Lung Biotechnology PBCInventors: Hitesh Batra, Sudersan M. Tuladhar, Sri Harsha Tummala, Raju Penmasta, David A. Walsh
-
Patent number: 10081613Abstract: Compounds of the formula 1 wherein, R is hydrogen, alkyl or substituted alkyl, aryl or substituted aryl, are useful intermediates in the synthesis of fragrance ingredients such as Ambrox 2Type: GrantFiled: July 6, 2017Date of Patent: September 25, 2018Assignee: Givaudan, S.A.Inventors: Fridtjof Schröder, Urs Mueller, Jürg Daniel Oetiker
-
Patent number: 10005753Abstract: The present invention is directed to methods for preparing Beraprost and novel synthetic intermediates for Beraprost. In one aspect, a process is provided to produce a pharmaceutical compound represented by the general Formula (I) via a radical cyclization route. The process is completed in fewer steps than the known synthetic methods and may be conducted to prepare commercially useful quantities. In another aspect, synthetic methods are provided for producing Beraprost and its derivatives, which are stereoselective, efficient, scalable and economical. In another aspect, substantially isomerically pure compounds and intermediates are produced by the above processes.Type: GrantFiled: May 19, 2015Date of Patent: June 26, 2018Assignee: Lung Biotechnology PBCInventors: Hitesh Batra, Sudersan M. Tuladhar, Sri Harsha Tummala, Raju Penmasta, David A. Walsh
-
Patent number: 9969706Abstract: An improved method is described for making single isomers of synthetic benzoprostacyclin analog compounds, in particular the pharmacologically active 314-d isomer of beraprost. In contrast to the prior art, the method is stereoselective and requires fewer steps than the known methods for making these compounds.Type: GrantFiled: February 23, 2017Date of Patent: May 15, 2018Assignee: Lung Biotechnology PBCInventors: Vijay Sharma, Hitesh Batra, Sudersan Tuladhar
-
Patent number: 9834532Abstract: The present invention relates to a novel naphtho class of compounds as Stat3 pathway inhibitors and as cancer stem cell inhibitors; to methods of using such compounds to treat cancer; to methods of using such compounds to treat disorders in a mammal related to aberrent Stat3 pathway activity; to pharmaceutical compositions containing such compounds.Type: GrantFiled: September 29, 2014Date of Patent: December 5, 2017Assignee: BOSTON BIOMEDICAL, INC.Inventors: Zhiwei Jiang, Chiang Jia Li, Wei Li, David Leggett
-
Patent number: 9758500Abstract: The present invention relates to new types of processes for the improved preparation of homofarnesol, in particular of (3E,7E)-homofarnesol and homofarnesol preparations with an increased content of (3E,7E)-homofarnesol (also referred to as all E-homofarnesol).Type: GrantFiled: October 12, 2016Date of Patent: September 12, 2017Assignee: BASF SEInventors: Melanie Weingarten, Hansgeorg Ernst, Wolfgang Siegel, Ekkehard Winterfeldt, Reinhard W. Hoffmann
-
Patent number: 9732056Abstract: Compounds of the formula 1 wherein, R is hydrogen, alkyl or substituted alkyl, aryl or substituted aryl, are useful intermediates in the synthesis of fragrance ingredients such as Ambrox 2Type: GrantFiled: September 15, 2015Date of Patent: August 15, 2017Assignee: Givaudan, S.A.Inventors: Fridtjof Schröder, Urs Mueller, Jurg Daniel Oetiker
-
Patent number: 9493385Abstract: The present invention relates to new types of processes for the improved preparation of homofarnesol, in particular of (3E,7E)-homofarnesol and homofarnesol preparations with an increased content of (3E,7E)-homofarnesol (also referred to as all E-homofarnesol).Type: GrantFiled: July 21, 2015Date of Patent: November 15, 2016Assignee: BASF SEInventors: Melanie Weingarten, Hansgeorg Ernst, Wolfgang Siegel, Ekkehard Winterfeldt, Reinhard W. Hoffmann
-
Patent number: 9381184Abstract: The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, methods of producing these naphthofuran compounds, polymorphs, purified compositions and/or particle forms, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof.Type: GrantFiled: March 10, 2015Date of Patent: July 5, 2016Assignee: Boston Biomedical, Inc.Inventors: Chiang Jia Li, David Leggett, Youzhi Li, Wei Li
-
Patent number: 9376415Abstract: A compound derived from the culture product of an actinomycete and having an antitumor activity is provided. Provided is a compound represented by any one of formulas (I), (II) and (III) or an optical isomer thereof or a pharmaceutically acceptable salt thereof which can be isolated from the culture fluid of an actinomycete which belongs to the genus Streptomyces, wherein R1, R2, R5 and R6 each independently represent a hydrogen atom, a methyl group, a hydroxymethyl group, a hydroxyl group, or a double bond by which R1 and R2 or R5 and R6 are bonded; R3, R4, R7 and R8 each independently represent a methyl group or a hydroxymethyl group; and R9 represents a hydrogen atom or a hydroxyl group.Type: GrantFiled: March 24, 2010Date of Patent: June 28, 2016Assignee: NIPPON SUISAN KAISHA, LTD.Inventors: Seizo Sato, Fumie Iwata, Shoichi Yamada, Jiro Takeo, Akihisa Abe, Hiroyuki Kawahara
-
Patent number: 9353385Abstract: Provided are labdenediol diphosphate synthase polypeptides, sclareol synthase polypeptides, nucleic acid molecules encoding the labdenediol diphosphate synthase polypeptides and sclareol synthase polypeptides, and methods of using the labdenediol diphosphate synthase polypeptides, sclareol synthase polypeptides. Also provided are methods for producing labdenediol diphosphate, sclareol and (?)-ambroxide.Type: GrantFiled: July 30, 2013Date of Patent: May 31, 2016Assignee: Evolva, Inc.Inventors: Grace Eunyoung Park, Bryan N. Julien, Richard Burlingame
-
Patent number: 9217121Abstract: 4,8-Dimethyl-3,7-nonadien-2-ol in which the weight ratio of (E)-4,8-dimethyl-3,7-nonadien-2-ol to the sum of (E)- and (Z)-4,8-dimethyl-3,7-nonadien-2-ol is at least 80% or in which the weight ratio of (Z)-4,8-dimethyl-3,7-nonadien-2-ol to the sum of (E)- and (Z)-4,8-dimethyl-3,7-nonadien-2-ol is at least 80%, is used as fragrance. The fragrances have a unique rose-like, floral character. Citrus-like, minty, green accompanying notes reminiscent of rhubarb arise.Type: GrantFiled: January 24, 2014Date of Patent: December 22, 2015Inventors: Stefan Rüdenauer, Ralf Pelzer, Wolfgang Krause
-
Patent number: 9084766Abstract: The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, methods of producing these naphthofuran compounds, polymorphs, purified compositions and/or particle forms, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof.Type: GrantFiled: March 21, 2011Date of Patent: July 21, 2015Assignee: Boston Biomedical, Inc.Inventors: Chiang Jia Li, David Leggett, Youzhi Li, Wei Li
-
Publication number: 20150142085Abstract: Pharmaceutical compositions and methods for treating and/or preventing age-related macular degeneration with melatonin analogues are provided.Type: ApplicationFiled: July 21, 2014Publication date: May 21, 2015Inventors: David Baron, Keisuke Hirai, Yasushi Shintani, Osamu Uchikawa
-
Patent number: 9028977Abstract: The present invention relates to a novel compound of Formula 1, a method for manufacturing the same, and an organic electronic device using the same, and the novel compound according to the present invention may act as a hole injection, hole transport, electron injection and transport, or light emitting material in an organic light emitting device and an organic electronic device, and the device according to the present invention shows excellent properties in terms of efficiency, a driving voltage, and stability.Type: GrantFiled: September 23, 2009Date of Patent: May 12, 2015Assignee: LG Chem, Ltd.Inventors: Jae-Soon Bae, Ji-Eun Kim, Jeung-Gon Kim, Jun-Gi Jang
-
Publication number: 20150094476Abstract: Compounds of the formula 1 wherein, R is hydrogen, alkyl or substituted alkyl, aryl or substituted aryl, are useful intermediates in the synthesis of fragrance ingredients such as Ambrox 2Type: ApplicationFiled: December 8, 2014Publication date: April 2, 2015Inventors: Fridtjof SCHRÖDER, Urs MUELLER, Jürg Daniel OETIKER
-
Patent number: 8981131Abstract: The present invention provides compounds represented by formula I: wherein, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13 and X are as defined in the specification, in all its stereoisomeric and tautomeric forms and mixtures thereof in all ratios, and its pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable polymorphs and prodrugs. These compounds are useful for treatment of inflammatory disorders including those caused by elevated levels of proinflammatory cytokines such as Tumor Necrosis Factor (TNF-? and/or interleukins (IL-1?, IL-6, IL-8). The invention also relates to processes for the manufacture of compounds of formula 1 and pharmaceutical compositions containing them.Type: GrantFiled: July 25, 2008Date of Patent: March 17, 2015Assignee: Piramal Enterprises LimitedInventors: Dilip Narayanrao Bhedi, Ram Asrey Vishwakarma, Vaishali Deka, Dattatray Maruti More, Manivannan Ramalingam, Ashish Suthar, Roda Dalal, Sapna Parikh, Aditi Amol Tannu
-
Publication number: 20150025255Abstract: The presently disclosed subject matter provides methods of preparing synthetic prostacyclin analogues, including Beraprost, either as racemic mixtures or as single stereoisomers. Also provided are novel synthetic intermediates for use in these methods.Type: ApplicationFiled: September 12, 2012Publication date: January 22, 2015Applicant: Lung Biotechnology Inc.Inventors: George Petros Yiannikouros, Panos Kalaritis, Chaminda Priyapushpa Gamage, Denis Viktorovich Arefyev
-
Publication number: 20150018410Abstract: The present invention relates to a novel naphtho class of compounds as Stat3 pathway inhibitors and as cancer stem cell inhibitors; to methods of using such compounds to treat cancer; to methods of using such compounds to treat disorders in a mammal related to aberrent Stat3 pathway activity; to pharmaceutical compositions containing such compounds.Type: ApplicationFiled: September 29, 2014Publication date: January 15, 2015Inventors: Zhiwei Jiang, Chiang Jia Li, Wei Li, David Leggett
-
Patent number: 8933253Abstract: Compounds of the formula 1 wherein, R is hydrogen, alkyl or substituted alkyl, aryl or substituted aryl are useful intermediates in the synthesis of fragrance ingredients such as Ambrox 2.Type: GrantFiled: December 21, 2011Date of Patent: January 13, 2015Assignee: Givaudan S.A.Inventors: Fridtjof Schröder, Urs Mueller, Jürg Daniel Oetiker
-
Publication number: 20140357682Abstract: Non ligand binding pocket antagonists for the human androgen receptor. The androgen receptor (AR) is a member of the Nuclear Receptor (NR) family and its role is to modulate the biological effects of the endogenous androgens, testosterone (tes) and dihydrotestosterone (DHT). Synthetic androgens and anti-androgens have therapeutic value in the treatment of various androgen dependent conditions, from regulation of male fertility to prostate cancer. Current treatment of prostate cancer (PCa) typically involves administration of ‘classical’ antiandrogens, competitive inhibitors of natural AR ligands, DHT and tes, for the ligand binding pocket (LBP) in the C-terminal ligand binding domain (LBD) of the AR. However, prolonged LBP-targeting can often lead to androgen resistance and alternative therapies and therapeutic strategies are urgently required. Disclosed herein are a class of non-steroidal, small molecule AR antagonists which inhibit the transcriptional activity of the AR by non LBP-mediated modulation.Type: ApplicationFiled: November 23, 2012Publication date: December 4, 2014Applicant: THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLYInventors: David George Lloyd, Darren Fayne, Mary Jane Meegan, Miriam Carr, Gemma Karena Kinsella, Laura Caboni, Wiliam Nicholas Jagoe, Billy Egan, Fernando Blanco
-
Patent number: 8877803Abstract: The present invention relates to a novel naphtho class of compounds as Stat3 pathway inhibitors and as cancer stem cell inhibitors; to methods of using such compounds to treat cancer; to methods of using such compounds to treat disorders in a mammal related to aberrant Stat3 pathway activity; to pharmaceutical compositions containing such compounds.Type: GrantFiled: September 10, 2008Date of Patent: November 4, 2014Assignee: Boston Biomedical, Inc.Inventors: Zhiwei Jiang, Chiang Jia Li, Wei Li, David Leggett
-
Patent number: 8871802Abstract: The present invention discloses novel naphtho[2,3-b]furan-4,9-diones and naphtho[2,3-b]thiophene-4,9-diones and methods of making and using the same. The present invention also discloses pharmaceutical compositions comprising novel naphtho[2,3-b]furan-4,9-dione or naphtho[2,3-b]thiophene-4,9-diones for the treatment of various indications including proliferative diseases.Type: GrantFiled: August 24, 2010Date of Patent: October 28, 2014Assignee: Zhoushan HaiZhongZhou Xinsheng Pharmaceuticals Co., Ltd.Inventors: Zhiwei Jiang, Aijin Wang, Xian Li, Qingrong Li, Hongwei Hu, Jiali Xu, Yuesong Hu, Yan Ye
-
Publication number: 20140314746Abstract: The invention includes novel methods of treating or preventing fibrosis in a subject afflicted with scleroderma, comprising administering to the subject a therapeutically effective amount of an agent that inhibits formation of at least one inflammasome signaling product in the subject.Type: ApplicationFiled: March 11, 2014Publication date: October 23, 2014Applicant: Philadelphia Health and Education Corporation, d/b/a Drexel University College of MedicineInventors: CAROL M. ARTLETT, PETER D. KATSIKIS
-
Publication number: 20140288314Abstract: A process provides for producing chiral prostacyclin derivatives of Formula (I) in high yield from meso anhydrides.Type: ApplicationFiled: March 24, 2014Publication date: September 25, 2014Applicant: United Therapeutics CorporationInventors: Hitesh Batra, Liang Guo
-
Publication number: 20140275237Abstract: In various embodiments the use of single isomer of beraprost as a therapeutic for the treatment of viral disease and other pathologies associated with the induction of a cytokine storm, such as influenza A viruses and the SARS-causing coronvirus and mutations thereof is provided.Type: ApplicationFiled: March 12, 2014Publication date: September 18, 2014Applicant: Gemmus Pharma Inc.Inventors: DARYL H. FAULDS, WILLIAM J. GUILFORD
-
Publication number: 20140275578Abstract: Compounds of the formula 1 wherein, R is hydrogen, alkyl or substituted alkyl, aryl or substituted aryl are useful intermediates in the synthesis of fragrance ingredients such as Ambrox 2.Type: ApplicationFiled: December 21, 2011Publication date: September 18, 2014Applicant: GIVAUDAN S.A.Inventors: Fridtjof Schröder, Jürg Daniel Oetiker
-
Publication number: 20140275573Abstract: An improved method is described for making single isomers of synthetic benzoprostacyclin analogue compounds, in particular the pharmacologically active 314-d isomer of beraprost. In contrast to the prior art, the method is stereoselective and requires fewer steps than the known methods for making these compounds.Type: ApplicationFiled: June 3, 2014Publication date: September 18, 2014Applicant: LUNG BIOTECHNOLOGY INC.Inventors: Vijay Sharma, Hitesh Batra, Sudersan Tuladhar
-
Publication number: 20140249193Abstract: The present invention provides compounds that modulate protein translocation in mitochondria, compositions thereof, and methods of identifying, making and using these.Type: ApplicationFiled: April 12, 2012Publication date: September 4, 2014Applicant: The Regents of the University of CaliforniaInventors: Carla M. Koehler, Samuel A. Hasson, Kiyoko Miyata, Micheal A. Teitell, Deepa Dabir
-
Publication number: 20140235879Abstract: The present invention provides a preparation with improved disintegration property, a preparation showing improved bioavailability of a medicament, production methods thereof and the like. A rapidly disintegrating preparation comprising granules comprising a medicament coated with a coating layer containing sugar or sugar alcohol; and a disintegrant. A production method of a rapidly disintegrating preparation including a step of producing granules comprising a medicament, a step of forming a coating layer containing sugar or sugar alcohol on the obtained granules and a step of mixing the coated granules with a disintegrant and molding the mixture.Type: ApplicationFiled: January 30, 2014Publication date: August 21, 2014Applicant: Takeda Pharmaceutical Company LimitedInventors: Yutaka Tanoue, Tetsuya Matsuura, Yutaka Yamagata, Naoki Nagahara
-
Publication number: 20140235709Abstract: The present invention provides a preparation with improved disintegration property, a preparation showing improved bioavailability of a medicament, production methods thereof and the like. A rapidly disintegrating preparation comprising granules comprising a medicament coated with a coating layer containing sugar or sugar alcohol; and a disintegrant. A production method of a rapidly disintegrating preparation including a step of producing granules comprising a medicament, a step of forming a coating layer containing sugar or sugar alcohol on the obtained granules and a step of mixing the coated granules with a disintegrant and molding the mixture.Type: ApplicationFiled: January 30, 2014Publication date: August 21, 2014Applicant: Takeda Pharmaceutical Company LimitedInventors: Yutaka Tanoue, Tetsuya Matsuura, Yutaka Yamagata, Nacki Nagahara
-
Publication number: 20140227184Abstract: Methods of halogenating a carbon containing compound having an sp3 C—H bond are provided. Methods of fluorinating a carbon containing compound comprising halogenation with Cl or Br followed by nucleophilic substitution with F are provided. Methods of direct oxidative C—H fluorination of a carbon containing compound having an sp3 C—H bond are provided. The halogenated products of the methods are provided.Type: ApplicationFiled: August 20, 2012Publication date: August 14, 2014Applicant: The Trustees of Princeton UniversityInventors: John T. Groves, Wei Liu, Xiongyi Huang
-
Publication number: 20140199741Abstract: A process for manufacturing tetrahydrofuran, tetrahydropyran and, more generally, cycloether derivatives through the cyclodehydration of 1,4- or 1,5-diols. More specifically, the process of the invention involves (i) the stereoselective cyclodehydration in water of 1,4- or 1,5-diols including at least one chiral tertiary alcohol functional group with retention of the initial chirality, and/or (ii) the cyclodehydration in water of 1,4- or 1,5-diols, said diols being non-miscible with and/or non-soluble in water, into corresponding cycloether derivatives, by bringing the reaction mixture to high temperature water (HTW) conditions and/or by mixing the aqueous reaction mixture with a solid catalyst, such as for example a smectite clay. Also, the use of the process for manufacturing ambrafuran, especially (?)-ambrafuran and other cycloether derivatives.Type: ApplicationFiled: July 13, 2012Publication date: July 17, 2014Applicant: KOSTE BIOCHEMICALSInventor: Charles Carey
-
Patent number: 8779170Abstract: An improved method is described for making single isomers of synthetic benzoprostacyclin analogue compounds, in particular the pharmacologically active 314-d isomer of beraprost. In contrast to the prior art, the method is stereoselective and requires fewer steps than the known methods for making these compounds.Type: GrantFiled: June 15, 2012Date of Patent: July 15, 2014Assignee: Lung Biotechnology Inc.Inventors: Vijay Sharma, Hitesh Batra, Sudersan Tuladhar
-
Patent number: 8765980Abstract: A process for the preparation of ?,?-unsaturated-?, ?-disubstituted esters 1 with high E/Z- and ?,?/?,?-ratios, Formula (1) by reacting at a temperature of between about 130 and 170 degrees centigrade the conjugated malonate Formula (3) with, a group I, II or III metal halide or an organic cation/halide anion pair, an inorganic proton source and a polar solvent.Type: GrantFiled: December 17, 2010Date of Patent: July 1, 2014Assignee: Givaudan S.A.Inventors: Fridtjof Schröder, Urs Mueller, Peter Gygax
-
Publication number: 20140179754Abstract: Tricylic ether carbamates that inhibit HIV proteolytic enzymes and processes for preparing the compounds are describes. Methods of using the disclosed compounds for treating patients infected with HIV are also described.Type: ApplicationFiled: October 8, 2013Publication date: June 26, 2014Applicants: NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY, PURDUE RESEARCH FOUNDATIONInventors: Arun K. GHOSH, Chun-Xiao Xu, Hiroaki Mitsuya, Garth Parham
-
Patent number: 8728708Abstract: Disclosed is a photosensitive resin composition comprising: (Component A) an oxime sulfonate compound represented by Formula (1); (Component B) a resin comprising a constituent unit having an acid-decomposable group that is decomposed by an acid to form a carboxyl group or a phenolic hydroxy group; and (Component C) a solvent wherein in Formula (1) R1 denotes an alkyl group, an aryl group, or a heteroaryl group, each R2 independently denotes a hydrogen atom, an alkyl group, an aryl group, or a halogen atom, Ar1 denotes an o-arylene group or an o-heteroarylene group, X denotes O or S, and n denotes 1 or 2, provided that of two or more R2s present in the compound, at least one denotes an alkyl group, an aryl group, or a halogen atom.Type: GrantFiled: February 27, 2013Date of Patent: May 20, 2014Assignee: FUJIFILM CorporationInventors: Kyouhei Sakita, Wataru Kikuchi, Masatoshi Yumoto, Masanori Hikita